FCCC LOGO Faculty Publications
Zelenetz AD , Gordon LI , Abramson JS , Advani RH , Bartlett NL , Caimi PF , Chang JE , Chavez JC , Christian B , Fayad LE , Glenn MJ , Habermann TM , Lee Harris N , Hernandez-Ilizaliturri F , Kaminski MS , Kelsey CR , Khan N , Krivacic S , LaCasce AS , Mehta A , Nademanee A , Rabinovitch R , Reddy N , Reid E , Roberts KB , Smith SD , Snyder ED , Swinnen LJ , Vose JM , Dwyer MA , Sundar H
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
J Natl Compr Canc Netw. 2019 Jun 1;17(6) :650-661
Back to previous list
Abstract
Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.
Notes
Zelenetz, Andrew D Gordon, Leo I Abramson, Jeremy S Advani, Ranjana H Bartlett, Nancy L Caimi, Paolo F Chang, Julie E Chavez, Julio C Christian, Beth Fayad, Luis E Glenn, Martha J Habermann, Thomas M Lee Harris, Nancy Hernandez-Ilizaliturri, Francisco Kaminski, Mark S Kelsey, Christopher R Khan, Nadia Krivacic, Susan LaCasce, Ann S Mehta, Amitkumar Nademanee, Auayporn Rabinovitch, Rachel Reddy, Nishitha Reid, Erin Roberts, Kenneth B Smith, Stephen D Snyder, Erin D Swinnen, Lode J Vose, Julie M Dwyer, Mary A Sundar, Hema eng J Natl Compr Canc Netw. 2019 Jun 1;17(6):650-661. doi: 10.6004/jnccn.2019.0029.